Tafinlar (dabrafenib)

Initially diagnosed with BRAF V600E-mutated melanoma, he received Dabrafenib and Trametinib...Despite initial treatment with Triptorelin, Docetaxel, and Abiraterone, disease progression occurred...This case illustrates the value of precision medicine and the role of liquid biopsy in guiding immunotherapy decisions for complex oncological cases. It supports the relevance of molecular profiling in selecting effective treatments beyond standard indications.

While dabrafenib and trametinib were well tolerated, treatment feasibility was restricted. These findings emphasize the urgent need for more robust research to identify effective therapeutic strategies for this molecular subgroup.

P4, N=100, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2030 --> Dec 2032 | Trial primary completion date: Dec 2029 --> Dec 2032

P2, N=49, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

Neoadjuvant therapy shows promise in improving resectability for unresectable and poorly differentiated thyroid cancers, with 51% of patients achieving R0 resection. Future studies should investigate optimal therapy selection, timing, dosing, and long-term outcomes, including disease-specific survival and patient-reported measures.

Pyrexia syndrome is a common adverse event in patients on dabrafenib and trametinib. Patients who develop pyrexia syndrome unexpectedly stayed on treatment longer in our cohort, highlighting the importance of early recognition and supportive management to maintain patients on therapy.

P2, N=40, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jan 2026

P1, N=30, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026

P2, N=280, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

Gliomas can be devastating for children and their families. In addition to providing a cost-effective option, treatment with D+T allows patients to be managed away from the hospital and so may help alleviate NHS capacity issues.

As expected, none of the BRAF KIAA1549 fusion+ pLGG tumors were sensitive to dabrafenib treatment. Two out of the three tumors demonstrated predicted sensitivity to trametinib, whereas one tumor did not. While no clinical correlates were measured in this proof-of-concept study, this mixed response to MEK inhibition on SLiCE is representative of heterogeneous real-world clinical responses. Together, these data demonstrate the feasibility of SLiCE to become a new functional biomarker of response in a tumor type where functional models are exceptionally rare, establishing a foundation for future individualized treatment strategies.

This case highlights that the co-occurrence of BRAF V600E and biallelic BRCA2 mutations may confer a unique clinical phenotype with suboptimal or transient responses to both BRCA-directed therapies (platinum, olaparib) and BRAF/MEK inhibition. It underscores the complexity of precision oncology in PDAC, where genotype does not always predict therapeutic response, potentially due to factors like tumor heterogeneity, stromal barriers, or undiscovered resistance mechanisms. Future large-scale studies are needed to define prognostic implications and explore potential combination strategies (e.g., BRAF/MEK + PARP inhibitors) for this rare molecular cohort.